Non-cystic fibrosis bronchiectasis (NCFBE) is an inflammatory pulmonary condition that characteristically causes permanent widening of the airways, making it difficult for patients to properly clear mucus. This excessive mucus leads to recurrent lung infections and damage—fueling a cycle of chronic inflammation. New treatment strategies are changing how NCFBE is managed. This activity discusses how to utilize these advancements to develop safe and efficacious treatment regimens that address the underlying pathophysiology of NCFBE.
Upon completion of this activity, participants should be better able to:
Staff Clinician
Critical Care Medicine and Pulmonary Branch
National Heart, Lung, and Blood Institute
National Institutes of Health
Bethesda, MD
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Pamela J. McShane, MD, has the following relevant financial relationships: AN2 Therapeutics, Armata Pharmaceuticals, Boehringer Ingelheim, Insmed, Renovian (Research funding); Boehringer Ingelheim (Other: Steering Committee Member).
All relationships have ended as of August 2025. All of the relevant financial relationships listed for this individual have been mitigated according to RMEI policies.
In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
To receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at [email protected].
Users must:
There is no fee to participate.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Featured RMEI CE Activities
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources
